Qlt Inc (QLTI) 6.44 $QLTI
QLT Inc. (QLTI) is Overbought: Is A Drop Coming? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 12, 8:48AM CDT
QLT Inc. (QLTI) is Overbought: Is A Drop Coming?
QLT Announces Positive Final Results From Phase 1b Retreatment Trial With Oral Synthetic cis-Retinoid (QLT091001) in Subjects With LCA or RP Due to Mutations in RPE65 or LRAT
GlobeNewswire - Fri Sep 12, 6:00AM CDT
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company"
today announced positive final results from its international, multi-center, Phase 1b clinical trial of repeated treatments of oral QLT091001 in subjects with Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) due to inherited genetic mutations in retinal pigment epithelium (RPE65) or lecithin:retinol acyltransferase (LRAT). The results, which confirm the top line efficacy and safety outcomes reported from the study in February 2014, will be presented tomorrow, September 13, 2014, at the 47 Annual Scientific Meeting of The Retina Society in Philadelphia, PA, by Dr. Hendrik Scholl, the Dr. Frieda Derdeyn Bambas Professor of Ophthalmology and Director of the Visual Neurophysiology Service at the Wilmer Eye Institute at the Johns Hopkins Hospital, and an investigator in the trial. The presentation slides will be made available on QLT's web site following the Retina Society Meeting.
Auxilium Pharmaceuticals to Restructure, Cut Jobs by 30% - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 3:35PM CDT
Auxilium Pharmaceuticals, Inc. (AUXL) announced certain restructuring steps following a comprehensive assessment of Auxilium Pharma's product portfolio in a bid to lower operating costs and drive growth.
Moving Average Crossover Alert: QLT Inc. (QLTI) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 9:45AM CDT
Moving Average Crossover Alert: QLT Inc. (QLTI)
Auxilium Posts Wider-than-Expected Loss, Outlook Maintained - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 1:10PM CDT
The share price of Auxilium Pharmaceuticals, Inc. (AUXL) fell 9.6% after the company announced its second-quarter results on Aug 7. However, share prices have however recovered approximately 3.1% thereafter.
Nasdaq stocks posting largest percentage decreases
AP - Thu Aug 07, 12:31PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
QLT Announces Adoption of Advance Notice Policy
GlobeNewswire - Thu Aug 07, 6:08AM CDT
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company" announces the approval by its board of directors of an advance notice policy (the "Advance Notice Policy" regarding director elections, as described below.
Auxilium Pharmaceuticals, Inc. Announces Second Quarter 2014 Financial Results
PR Newswire - Thu Aug 07, 5:00AM CDT
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced financial results for the second quarter ending June 30, 2014. The Company highlighted important corporate, commercial, regulatory and clinical development updates from the quarter.
QLT Q2 Loss Widens, Focus on Impending Merger with Auxilium - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 06, 9:50AM CDT
QLT (QLTI) reported a wider loss in the second quarter.
Downgrade Alert for QLT (QLTI)
Comtex SmarTrend(R) - Wed Aug 06, 7:07AM CDT
QLT (NASDAQ:QLTI) was downgraded from Buy to Neutral at Roth Capital today. The stock closed yesterday at $5.80 on volume of 39,000 shares, below average daily volume of 267,000. There is potential upside of 16.2% for shares of QLT based on a current price of $5.81 and an average consensus analyst price target of $6.75. QLT shares have support at the 50-day moving average (MA) of $5.67 and additional support at the 200-day MA of $5.66.
QLT Announces Second Quarter 2014 Results
GlobeNewswire - Tue Aug 05, 6:07AM CDT
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company" is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. The Company reported financial results today for the second quarter ended June 30, 2014. Unless otherwise specified, all amounts are reported in U.S. dollars and in accordance with U.S. GAAP.
QLT Inc. (QLTI) Soars: Stock Adds 7.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 7:51AM CDT
QLT Inc. (QLTI) was a big mover last session, as its shares rose nearly 8% on the day.
QLT Announces Publication in The Lancet of Phase 1b Data for QLT091001 in Leber Congenital Amaurosis Due to LRAT or RPE65 Mutations
GlobeNewswire - Mon Jul 14, 6:00AM CDT
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company" today announced the publication of data from its Phase 1b proof-of-concept trial of QLT091001 in subjects with Leber Congenital Amaurosis (LCA) due to inherited genetic mutations in retinal pigment epithelium (RPE65) or lecithin:retinol acyltransferase (LRAT) in The Lancet. The peer-reviewed journal article is available first in the online edition of The Lancet at www.thelancet.com. In the study, treatment for 7 days with oral QLT091001 demonstrated a restoration of clinically meaningful visual function in 11 of the 14 LCA patients, as measured by improvement in Goldmann Visual Fields (GVF) or visual acuity. Self-reported or parent-reported improvements in activities of daily living supported these findings.
Salix-Cosmo to Merge in Tax-Saving Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 4:35PM CDT
Following the merger, the combined entity will be renamed Salix Pharmaceuticals, plc. (SLXP) with Salix becoming a wholly-owned subsidiary of Irish domiciled Cosmo Technologies.
INVESTOR ALERT: The Law Offices of Vincent Wong Investigates the Sale of Auxilium Pharmaceuticals Inc.: - AUXL
PR Newswire - Tue Jul 08, 4:04PM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Auxilium Pharmaceuticals Inc. (NasdaqGS: AUXL) ("Auxilium" in connection with the sale of the Company to QLT Inc. (NasdaqGS: QLTI).
AUXILIUM PHARMACEUTICALS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Auxilium Pharmaceuticals Inc. Board of Directors in Connection With the Proposed Sale of the Company to QLT Inc.
Business Wire - Mon Jul 07, 5:15PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Auxilium Pharmaceuticals Inc. ("Auxilium" or the "Company" (NASDAQ:AUXL) for potential breaches of fiduciary duties in connection with the sale of the Company to QLT Inc. ("QLT" in an all-stock deal valued at approximately $851 million. The Company's stockholders will only receive 3.1359 QLT shares for each share of Auxilium common stock they own. Ultimately, Auxilium shareholders will own 76 percent of the combined company, while QLT shareholders will own the remaining 24 percent. Auxilium will be re-incorporating to Canada.
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Auxilium Pharmaceuticals, Inc. in Connection with the Sale of the Company
Business Wire - Mon Jul 07, 6:00AM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Auxilium Pharmaceuticals, Inc. ("Auxilium" or the "Company" (Nasdaq: AUXL) relating to the proposed acquisition by QLT, Inc. ("QLT" .
The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, MannKind, Auxilium Pharmaceuticals, QLT and AbbVie
PR Newswire - Thu Jul 03, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Vertex Pharmaceuticals (Nasdaq:VRTX-Free Report), MannKind Corporation (Nasdaq:MNKD-Free Report), Auxilium Pharmaceuticals (Nasdaq:AUXL-Free Report), QLT Inc. (Nasdaq:QLTI-Free Report) and AbbVie (NYSE:ABBV-Free Report).
SHAREHOLDER ALERT: Brower Piven Announces The Investigation Of Auxilium Pharmaceuticals Inc. In Connection With The Proposed Sale Of The Company To QLT Inc.
Business Wire - Wed Jul 02, 2:55PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the board of directors of Auxilium Pharmaceuticals Inc. ("Auxilium" or the "Company" (NASDAQ: AUXL) relating to the proposed buyout of the Company by QLT Inc. ("QLT" .
Biotech Stock Roundup: Vertex Jumps on Phase III Data, MannKind Scores FDA Approval - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 02, 9:41AM CDT
Highlights last week include positive phase III data on Vertex's cystic fibrosis combination, FDA approval of MannKind's Afrezza and Auxilium's merger deal with QLT Inc.
QLT Inc. (QLTI) is Overbought: Is A Drop Coming? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 12, 8:48AM CDT
QLT Inc. (QLTI) is Overbought: Is A Drop Coming?
QLT Announces Positive Final Results From Phase 1b Retreatment Trial With Oral Synthetic cis-Retinoid (QLT091001) in Subjects With LCA or RP Due to Mutations in RPE65 or LRAT
GlobeNewswire - Fri Sep 12, 6:00AM CDT
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company"
today announced positive final results from its international, multi-center, Phase 1b clinical trial of repeated treatments of oral QLT091001 in subjects with Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) due to inherited genetic mutations in retinal pigment epithelium (RPE65) or lecithin:retinol acyltransferase (LRAT). The results, which confirm the top line efficacy and safety outcomes reported from the study in February 2014, will be presented tomorrow, September 13, 2014, at the 47 Annual Scientific Meeting of The Retina Society in Philadelphia, PA, by Dr. Hendrik Scholl, the Dr. Frieda Derdeyn Bambas Professor of Ophthalmology and Director of the Visual Neurophysiology Service at the Wilmer Eye Institute at the Johns Hopkins Hospital, and an investigator in the trial. The presentation slides will be made available on QLT's web site following the Retina Society Meeting. Auxilium Pharmaceuticals to Restructure, Cut Jobs by 30% - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 3:35PM CDT
Auxilium Pharmaceuticals, Inc. (AUXL) announced certain restructuring steps following a comprehensive assessment of Auxilium Pharma's product portfolio in a bid to lower operating costs and drive growth.
Moving Average Crossover Alert: QLT Inc. (QLTI) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 9:45AM CDT
Moving Average Crossover Alert: QLT Inc. (QLTI)
Auxilium Posts Wider-than-Expected Loss, Outlook Maintained - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 1:10PM CDT
The share price of Auxilium Pharmaceuticals, Inc. (AUXL) fell 9.6% after the company announced its second-quarter results on Aug 7. However, share prices have however recovered approximately 3.1% thereafter.
Nasdaq stocks posting largest percentage decreases
AP - Thu Aug 07, 12:31PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
QLT Announces Adoption of Advance Notice Policy
GlobeNewswire - Thu Aug 07, 6:08AM CDT
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company"
announces the approval by its board of directors of an advance notice policy (the "Advance Notice Policy" regarding director elections, as described below. Auxilium Pharmaceuticals, Inc. Announces Second Quarter 2014 Financial Results
PR Newswire - Thu Aug 07, 5:00AM CDT
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced financial results for the second quarter ending June 30, 2014. The Company highlighted important corporate, commercial, regulatory and clinical development updates from the quarter.
QLT Q2 Loss Widens, Focus on Impending Merger with Auxilium - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 06, 9:50AM CDT
QLT (QLTI) reported a wider loss in the second quarter.
Downgrade Alert for QLT (QLTI)
Comtex SmarTrend(R) - Wed Aug 06, 7:07AM CDT
QLT (NASDAQ:QLTI) was downgraded from Buy to Neutral at Roth Capital today. The stock closed yesterday at $5.80 on volume of 39,000 shares, below average daily volume of 267,000. There is potential upside of 16.2% for shares of QLT based on a current price of $5.81 and an average consensus analyst price target of $6.75. QLT shares have support at the 50-day moving average (MA) of $5.67 and additional support at the 200-day MA of $5.66.
QLT Announces Second Quarter 2014 Results
GlobeNewswire - Tue Aug 05, 6:07AM CDT
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company"
is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. The Company reported financial results today for the second quarter ended June 30, 2014. Unless otherwise specified, all amounts are reported in U.S. dollars and in accordance with U.S. GAAP. QLT Inc. (QLTI) Soars: Stock Adds 7.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 7:51AM CDT
QLT Inc. (QLTI) was a big mover last session, as its shares rose nearly 8% on the day.
QLT Announces Publication in The Lancet of Phase 1b Data for QLT091001 in Leber Congenital Amaurosis Due to LRAT or RPE65 Mutations
GlobeNewswire - Mon Jul 14, 6:00AM CDT
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company"
today announced the publication of data from its Phase 1b proof-of-concept trial of QLT091001 in subjects with Leber Congenital Amaurosis (LCA) due to inherited genetic mutations in retinal pigment epithelium (RPE65) or lecithin:retinol acyltransferase (LRAT) in The Lancet. The peer-reviewed journal article is available first in the online edition of The Lancet at www.thelancet.com. In the study, treatment for 7 days with oral QLT091001 demonstrated a restoration of clinically meaningful visual function in 11 of the 14 LCA patients, as measured by improvement in Goldmann Visual Fields (GVF) or visual acuity. Self-reported or parent-reported improvements in activities of daily living supported these findings. Salix-Cosmo to Merge in Tax-Saving Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 4:35PM CDT
Following the merger, the combined entity will be renamed Salix Pharmaceuticals, plc. (SLXP) with Salix becoming a wholly-owned subsidiary of Irish domiciled Cosmo Technologies.
INVESTOR ALERT: The Law Offices of Vincent Wong Investigates the Sale of Auxilium Pharmaceuticals Inc.: - AUXL
PR Newswire - Tue Jul 08, 4:04PM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Auxilium Pharmaceuticals Inc. (NasdaqGS: AUXL) ("Auxilium"
in connection with the sale of the Company to QLT Inc. (NasdaqGS: QLTI). AUXILIUM PHARMACEUTICALS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Auxilium Pharmaceuticals Inc. Board of Directors in Connection With the Proposed Sale of the Company to QLT Inc.
Business Wire - Mon Jul 07, 5:15PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Auxilium Pharmaceuticals Inc. ("Auxilium" or the "Company"
(NASDAQ:AUXL) for potential breaches of fiduciary duties in connection with the sale of the Company to QLT Inc. ("QLT" in an all-stock deal valued at approximately $851 million. The Company's stockholders will only receive 3.1359 QLT shares for each share of Auxilium common stock they own. Ultimately, Auxilium shareholders will own 76 percent of the combined company, while QLT shareholders will own the remaining 24 percent. Auxilium will be re-incorporating to Canada. SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Auxilium Pharmaceuticals, Inc. in Connection with the Sale of the Company
Business Wire - Mon Jul 07, 6:00AM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Auxilium Pharmaceuticals, Inc. ("Auxilium" or the "Company"
(Nasdaq: AUXL) relating to the proposed acquisition by QLT, Inc. ("QLT" . The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, MannKind, Auxilium Pharmaceuticals, QLT and AbbVie
PR Newswire - Thu Jul 03, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Vertex Pharmaceuticals (Nasdaq:VRTX-Free Report), MannKind Corporation (Nasdaq:MNKD-Free Report), Auxilium Pharmaceuticals (Nasdaq:AUXL-Free Report), QLT Inc. (Nasdaq:QLTI-Free Report) and AbbVie (NYSE:ABBV-Free Report).
SHAREHOLDER ALERT: Brower Piven Announces The Investigation Of Auxilium Pharmaceuticals Inc. In Connection With The Proposed Sale Of The Company To QLT Inc.
Business Wire - Wed Jul 02, 2:55PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the board of directors of Auxilium Pharmaceuticals Inc. ("Auxilium" or the "Company"
(NASDAQ: AUXL) relating to the proposed buyout of the Company by QLT Inc. ("QLT" . Biotech Stock Roundup: Vertex Jumps on Phase III Data, MannKind Scores FDA Approval - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 02, 9:41AM CDT
Highlights last week include positive phase III data on Vertex's cystic fibrosis combination, FDA approval of MannKind's Afrezza and Auxilium's merger deal with QLT Inc.
